Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2025)

Maxcyte (MXCT) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $6000.0 as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment changed N/A to $6000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35000.0 through Dec 2025, up 126.92% year-over-year, with the annual reading at $35000.0 for FY2025, 126.92% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $6000.0 at Maxcyte, up from -$136000.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $130000.0 in Q1 2024, with the low at -$260000.0 in Q2 2024.
  • Average Asset Writedowns and Impairment over 3 years is -$19250.0, with a median of -$1500.0 recorded in 2023.
  • Peak annual rise in Asset Writedowns and Impairment hit 138.46% in 2025, while the deepest fall reached 50.0% in 2025.
  • Over 3 years, Asset Writedowns and Impairment stood at -$50000.0 in 2023, then tumbled by 420.0% to -$260000.0 in 2024, then skyrocketed by 102.31% to $6000.0 in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $6000.0, -$136000.0, and $100000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.